Martina Zussino
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Letter: Real-Life Improvement in Quality of Life With Delgocitinib in Chronic Hand Eczema.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 19, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Letter: Tralokinumab Dose Spacing in Moderate-to-Severe Atopic Dermatitis: A Real-World Case Series.
Letter: Tralokinumab Dose Spacing in Moderate-to-Severe Atopic Dermatitis: A Real-World Case Series.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: February 17, 2026
Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.
Journal: Dermatology and therapy
Published: December 19, 2025
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.
Journal: Clinical and experimental dermatology
Published: October 21, 2025
Dual Biologic Therapy With Dupilumab and Risankizumab for Coexistent Prurigo Nodularis and Psoriasis.
Journal: International journal of dermatology
Published: August 21, 2025
Effectiveness of Dupilumab and Tralokinumab in Treating Nummular Eczema.
Journal: International journal of dermatology
Published: July 05, 2025
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study.
Journal: The Journal of dermatology
Published: January 24, 2025
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors.
Journal: The Journal of dermatological treatment
Published: October 13, 2024
Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single-centre study on 485 patients.
Journal: The Australasian journal of dermatology
Published: March 10, 2024
Antinuclear matrix protein 2 antibody-positive dermatomyositis: a rare entity.
Journal: Italian journal of dermatology and venereology
Published: January 16, 2024
Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 10, 2023
Last Updated: 09/26/2026